modelSparteine
Extends from Pharmacolibrary.Drugs.ATC.C.C01BA04.
Information
| name: | Sparteine | |
| ATC code: | C01BA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 2.0 | L |
| clearance: | 4.7 | mL/min/kg |
| other parameters in model implementation | ||
Sparteine is a naturally occurring alkaloid formerly used as an antiarrhythmic agent (class 1a) for heart rhythm disorders. It has also been studied as an oxytocic agent. Sparteine is not currently approved or widely used in modern clinical practice due to safety concerns and the availability of safer alternatives.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers, both sexes. Oral administration.
References
Bergmann, TK, et al., & Brosen, K (2001). Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. European journal of clinical pharmacology 57(2) 123–127. DOI:10.1007/s002280100284 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11417443
Jazwinska-Tarnawska, E, et al., & Slawin, J (2001). The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. International journal of clinical pharmacology and therapeutics 39(7) 288–292. DOI:10.5414/cpp39288 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11471772
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)